Abstract
Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.
| Original language | English |
|---|---|
| Journal | Asian Journal of Surgery |
| DOIs | |
| Publication status | Published - 2019 Jan 1 |
Fingerprint
Keywords
- Breast carcinoma
- Fluorescein
- Sentinel lymph node biopsy
ASJC Scopus subject areas
- Surgery
Cite this
Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma : A single-center prospective study. / Chang, Young Woo; Lee, Hye Yoon; Lee, Chang Min; Jung, Seung Pil; Kim, Woo Young; Woo, Sang- Uk; Lee, Jae Bok; Son, Gil Soo.
In: Asian Journal of Surgery, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sentinel lymph node detection using fluorescein and blue light-emitting diodes in patients with breast carcinoma
T2 - A single-center prospective study
AU - Chang, Young Woo
AU - Lee, Hye Yoon
AU - Lee, Chang Min
AU - Jung, Seung Pil
AU - Kim, Woo Young
AU - Woo, Sang- Uk
AU - Lee, Jae Bok
AU - Son, Gil Soo
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.
AB - Background: Sentinel lymph node (SLN) biopsy is an essential procedure for lymph node staging in patients with breast carcinoma. Technetium-99m-labelled nanocolloid ( 99m Tc) is the most accurate and widely used lymphatic mapping agent; however, there are concerns pertaining to the associated exposure to radiation. Studies focusing on new agents are required. We aimed to evaluate the feasibility and safety of SLN detection using fluorescein and blue light-emitting diodes (LEDs) in breast carcinoma patients. Methods: In this prospective study, a total of 61 patients with breast carcinoma, requiring SLN biopsy, were enrolled. Both fluorescein and 99m Tc were intradermally injected into the areola of the affected breast of each patient. SLNs stained with fluorescein were detected using blue LED light first, and then, any remaining SLNs were detected using a gamma detection probe. The detection rate was analyzed, and the presence of complications was investigated. Results: SLNs dyed with fluorescein using blue LED light were visualized in 57 of 61 patients (93.4%). None of the patients experienced complications related to the use of fluorescein or blue LED light. Conclusions: The detection of SLNs using fluorescein and blue LED light was feasible and safe in patients with breast carcinoma. This technique involves the use of visible light, allowing for SLNs to be viewed with the naked eye, and is quantifiable, easy to use, and economical.
KW - Breast carcinoma
KW - Fluorescein
KW - Sentinel lymph node biopsy
UR - http://www.scopus.com/inward/record.url?scp=85063049943&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063049943&partnerID=8YFLogxK
U2 - 10.1016/j.asjsur.2019.03.005
DO - 10.1016/j.asjsur.2019.03.005
M3 - Article
C2 - 30904399
AN - SCOPUS:85063049943
JO - Asian Journal of Surgery
JF - Asian Journal of Surgery
SN - 1015-9584
ER -